Published in Hepatitis Weekly, April 30th, 2007
In this cohort, 93 percent of patients who were re-treated with BARACLUDE had undetectable viral load -...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.